Howard-Sparks M[au] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2004	1
2005	1
2007	1
2023	0

Page 1

Evaluation of O(3alpha)-, O(21)-di-(N(1)-methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl) 17alpha-hydroxy-5beta-pregnan-20-one as a novel potential antiangiogenic codrug.

Howard-Sparks M, Al-Ghananeem AM, Pearson AP, Crooks PA. Howard-Sparks M, et al. J Enzyme Inhib Med Chem. 2005 Oct;20(5):417-28. doi: 10.1080/14756360500220319. J Enzyme Inhib Med Chem. 2005. PMID: 16335049

A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug.

Howard-Sparks M, Al-Ghananeem AM, Crooks PA, Pearson AP. Howard-Sparks M, et al. Drug Dev Ind Pharm. 2007 Jun;33(6):677-82. doi: 10.1080/03639040601134108. Drug Dev Ind Pharm. 2007. PMID: 17613031

Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A.

Howard-Sparks M, Gawlikowski A; FDA. Howard-Sparks M, et al. PDA J Pharm Sci Technol. 2004 Jul-Aug;58(4):222-30. PDA J Pharm Sci Technol. 2004. PMID: 15368992

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

3 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year